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Ectopic ACTH secretion in the setting of breast cancer is extremely rare but when pres-
ent affects both the tumor’s behavior and the incidence of complications.  The patient, a 
58-year-old woman, first presented with a mass in her left breast as well as multiple os-
seous metastases and a right femur fracture. Laboratory data revealed a hypokalemic al-
kalosis.  Her plasma ACTH level was elevated. She was diagnosed with breast cancer with 
ectopic ACTH secretion, and underwent a left mastectomy and axillary lymph node dissec-
tion.  Histological examination demonstrated a poorly differentiated neuroendocrine car-
cinoma with ectopic ACTH secretion.  Although the signs and symptoms of ectopic ACTH 
secretion from a breast cancer are frequently subtle, the recognition of ectopic ACTH se-
cretion from breast cancer is important for patient management.
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The ectopic secretion of ACTH in the setting of 
cancer is well demonstrated in small-cell lung car-
cinoma, neuroendocrine tumors of the lung, thy-
mus, gastrointestinal tract, islet cell carcinoma of 
the pancreas, pheochromocytoma and medullary 
thyroid carcinoma (Isidori and Lenzi, 2007).  Many 
breast cancers are steroid hormone dependent and 
may influence the pathological course of the dis-
ease by stimulating the initial phase of steroid hor-
mone biosynthesis converting cholesterol to preg-
nenolone in the adrenal cortex (Wigg et al., 1999). 
Especially, in post-menopausal patients, most of 
the circulating estrogen is produced by the aroma-
tization of adrenal androgens in peripheral tissues. 
Therefore, it is speculated that ACTH would im-
pact the behavior of breast cancer.  However, ecto-
pic ACTH secretion from breast cancer is rare, and 
is associated with less than 1% of tumors (Isidori 
and Lenzi, 2007).  The incidence rate of neuroen-
docrine cells in breast cancer has been reported to 
be 21.0% (17/81 patients); however, none of the 17 
expressed ACTH (Yao et al., 2003).  Furthermore, 
it is subtle and produces few signs of clinically 
recognizable Cushing’s syndrome.  Consequently, 
assessment for ectopic ACTH expression is not 
routinely performed in the management of breast 
cancer.  Here, we report a case of immunohis-
tochemically confirmed ectopic ACTH secretion in 
a breast cancer patient, which was identified when 
she developed hypokalemic metabolic alkalosis.
 
Patient Report
 
The patient, a 58-year-old woman, was first pre-
sented with a 7-month history of a mass in her 
left breast.  On physical examination, she had an 
ulcerated 7 cm mass on her left breast. She had no 
Cushingoid features including central abdominal 
obesity, pigmentation, striae or facial hirsuitism.  A 
mammogram showed a high density, microlobulat-
ed, oval mass and pleomorphic segmental calcifi-
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µg/dL).  Her plasma ACTH level was elevated to 
83.5 pg/mL (normal range: 7.2–63.3 pg/mL).  Her 
serum aldosterone and renin levels were within the 
normal range.  Her daily urinary secretion of po-
tassium was 26.0 mEq/day, which was within nor-
mal range.  Her pituitary gland appeared normal 
on MRI.
 The patient was diagnosed as with presump-
tive stage IV breast cancer with suspected ectopic 
ACTH secretion.  She underwent a left mastectomy 
and axillary lymph node dissection for local con-
trol.  Histological examination of tissue obtained 
from the primary mass revealed a poorly differen-
tiated neuroendocrine carcinoma (Fig. 2).  One of 
12 axillary lymph nodes was positive for metastatic 
carcinoma.  The resected tissue was positive for 
synaptophysin on immunohistochemistry (Fig. 3), 
neuron-specific enolase, chromogranin A and 
ACTH (Fig. 4).  The tumor also expressed both 
estrogen and progesterone receptors.  Human epi-
dermal growth factor receptor type 2 expression 
was negative on immunostaining and fluorescence 
in situ hybridization. Ki-67 staining revealed that 
42 % of the cells were positive. 
Fig. 1.  Bilateral MLO views by mammography.  L-MLO view shows a high density, mi-
crolobulated, oval mass and pleomorphic segmental calcification, which is highly sugges-
tive of malignancy.  L, left; MLO, mediolateral oblique; R, right. 
cation (Fig. 1).  The tumor was oval and ill-defined 
with low echogenicity on ultrasound.  Aspiration 
biopsy cytology revealed suspected malignancy, 
which we presumed to be invasive ductal carci-
noma.  Computed tomographic scan demonstrated 
a mass at the left primary site.  Lesions consistent 
with osseous metastases were present in the cranial 
bone, sterna bone, ribs, vertebras, bilateral ilium 
and bilateral femurs.  These were also evident on a 
bone scintigram.  The right femur demonstrated a 
pathological fracture.  The patient also had a men-
ingeal metastasis.  The following tumor markers 
were elevated: carcinoembryonic antigen (CEA), 
135.0 ng/mL; carbohydrate antigen15-3 (CA15-3), 
138.5 U/mL; and national cancer center-ST439 
(NCC-ST439), 470.0 U/mL.  Breast cancer anti-
gen225 (BCA225) [93.6 U/mL] and tissue polypep-
tide antigen (TPA) [38 U/L] were within the normal 
range. 
 Initial serum chemistry studies revealed a 
hypokalemic metabolic alkalosis with a serum 
potassium level of 2.3 mEq/L, bicarbonate of 32.7 
mmol/L and pH 7.45.  The patient’s morning serum 
cortisol was 11.54 µg/dL (normal range: 6.7–22.6 
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Fig. 4.  Tumor cells with ACTH posi-
tivity are diffusely present.  Arrow 
shows a representative one (ACTH 
staining).  Bar = 100 µm.
Fig. 2.  Micrograph of 
the primary breast tumor.  
Eosinophilic tumor cells are 
shown (hematoxylin-eosin 
stain).  Bar = 100 µm.
Fig. 3.  Tumor cells with synap-
tophysin positivity are diffusely 
present.  Arrow shows a rep-
resentative one (synaptophysin 
staining).  Bar = 100 µm.
 Postoperatively, the patient 
was initially treated with letro-
zol for 2 months; however, her 
tumor marker values gradually 
increased, and administration 
of tamoxifen was initiated. 
Her plasma ACTH level was 
decreased to 36.4 pg/mL at 3 
postoperative months.  She also 
received radiation therapy to 
her vertebral metastasis.  Her 
hypokalemia was treated with 
potassium supplement.  She 
survives 3 months after surgery, 
remaining stable, and has been 
followed as an outpatient. 
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Table 1.  Cases of breast cancer with ACTH secretion
             Reference Patient Signs and symptoms ACTH Cortisol Pottasium Prognosis
 Age*  (pg/mL) (µg/dL) (mEq/L)
Cohle et al.  1979 70   540 48–72† 1.8
Woodard et al.  1981 44   188–190 54–87 1.8
Parker and Jackson  1984 69   290 78 1.6
Wigg et al.  1999 56   395 46 2.7
 
Pelte et al.  2004 50   240 Unknown 1.8
Present patient  2010 58   83.5 11.54 2.3
*Age (year).  Gender of patients, female.  
†mg/dL.
 
Discussion
 
In the breast, there are two main types of neuroen-
docrine tumors:  neuroendocrine differentiated car-
cinoma and breast carcinoma with neuroendocrine 
differentiation.  The latter is identified in 10 to 15% 
of breast cancers.  In the former, the majority of 
cells (more than 50%) display a neuroendocrine 
phenotype, often with a visible endocrine morphol-
ogy and expression of synaptophysin, neuron-spe-
cific enolase and /or chromogranin A by immuno-
histochemistry.  In our patient, the majority of cells 
were positive for synaptophysin, neuron-specific 
enolase and chromogranin A.  Furthermore, immu-
nostaining of ACTH was positive.  Therefore, we 
made the diagnosis of a neuroendocrine differenti-
ated carcinoma with ectopic ACTH secretion.
 In ectopic ACTH-producing breast cancer, 
few patients show symptoms of Cushing’s syn-
drome (Poddar et al., 2005).  It is contrastive to 
other ectopic ACTH-producing cancers such as 
lung and bronchial carcinoid tumors, in which 
the majority of patients present classical signs 
and symptoms of Cushing’s syndrome (Isidori et 
al., 2006).  It is probably because the amount of 
ACTH secreted by the tumors was insufficient to 
cause clinical manifestations of hormonal hyper-
activity.  To our knowledge, only 5 cases of breast 
cancer with Cushing’s syndrome were previously 
published (Cohle et al., 1979; Woodard et al., 1981; 
Parker and Jackson, 1984; Wigg et al., 1999; Pelte 
et al., 2004) (Table 1).  Reported patients had mean 
plasma ACTH levels as 188 to 540 ng/L, while our 
patient had a mean plasma ACTH level of 83.5 ng/
L (Table 1).  These suggest that the clinical presen-
tation of ectopic ACTH-producing breast cancer 
varies and reflects the underlying severity of the 
ACTH secretion.
 Although our patient lacked the classic stig-
mata of Cushing’s syndrome, ACTH-producing 
breast cancer was identified by hypokalemic meta-
Cushing’s syndrome like  
puffy face, pedal edema,  
hypertension and hyper- 
glycemia were present
Cushingoid appearance
Cushing’s syndrome was 
obvious, with moon face, 
plethora, hirsutism,  
a dorsocervical fat pad  
and centri petal obesity
Cushing’s syndrome was 
obvious, with facial fullness, 
central abdominal obesity 
and moderate facial hirsutism
Cushing’s syndrome was 
present
No Cushing’s syndrome
Died from sepsis 
(2 years after surgery)
 
 
Died from multiple metasta-
ses (10 years after surgery)
Died from pulmonary 
sufficiency and congestive 
heart failure 
(16 years after first surgery)
Died from pneumonitis and 
adult respiratory distress 
syndrome 
(11 months after surgery) 
Died from progressive heart 
failure and arrhythmia
Survive 
(3 months after surgery)
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bolic alkalosis enough to be required to correct 
one.  Hypokalemia has been reported to be present 
in 70% of the patients with ectopic ACTH secretion 
(Isidori et al., 2006).  Reported patients with ACTH-
producing breast cancer along with Cushing’s syn-
drome had severe hypokalemia (Table 1).  These 
suggest that ectopic ACTH secretion should be 
included in the differential of breast cancer patients 
with significant, unexplained hypokalemia. 
 Even though the ACTH level in our patient 
was low, ACTH could continuously stimulate the 
adrenal cortex in a sub-clinical manner to produce 
excess androgens, thereby modifying the course of 
the disease.  A recent finding is that up to 50% of 
patients with ectopic ACTH secretion may present 
osteoporosis or fractures (Ilias et al., 2005).  Our 
patient had a fracture of her right femur associated 
with a metastatic lesion.  It is possible that ectopic 
ACTH secretion not only influences disease pro-
gression but also increases the rate of associated 
complications.  Therefore, awareness of covert 
ectopic ACTH secretion is important in the man-
agement of breast cancers with neuroendocrine 
features. 
 The treatment of ectopic ACTH secretion 
requires a multimodal approach including surgery 
and medications to control tumor growth and as-
sociated symptoms.  If a single source is located, 
surgery is associated with complete remission in 
more than 80% of patients (Isidori et al., 2006). 
Patients with overt, severe ectopic ACTH secretion 
are treated with ketoconazole or metyrapone (Isidori 
and Lenzi, 2007; Pelte et al., 2004; Wigg et al., 
1999). 
 The prognosis of cancers with ectopic ACTH 
secretion depends on the primary tumor histology 
and the presence of metastases (Isidori and Lenzi, 
2007).  The survival of patients with an occult 
source of ACTH, but adequately controlled hyper-
cortisolemia, is reported to be favorable (Isidori et 
al., 2006).  In our patient, the tumor histology of 
a poorly differentiated neuroendocrine carcinoma 
with a high Ki-67 index and several metastases 
predicts a poor prognosis irrespective of the pa-
tient’s ACTH level.  
 In conclusion, ectopic ACTH secretion from 
a breast cancer is rare and the signs and symptoms 
are frequently subtle; however, recognition of ecto-
pic ACTH secretion is important for patient man-
agement. 
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